Tanja Gram Petersen

Tanja Gram Petersen

Auto-generated profile, based on publicly available information

Tanja Gram Petersen

Research unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense, Denmark

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2022 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
MCMaria Hornstrup Christensen
Maria Hornstrup Christensen
KRKatrine Hass Rubin
Katrine Hass Rubin
TPTanja Gram Petersen
Tanja Gram Petersen
ENEllen Aagaard Nøhr
Ellen Aagaard Nøhr
CVChristina Anne Vinter
Christina Anne Vinter
DJDorte Moeller Jensen
Dorte Moeller Jensen
Background: Gestational diabetes mellitus (GDM) is associated with adverse pregnancy outcomes and has maternal health implications reaching beyond the perinatal period. We aimed to investigate the incidence and severity of cardiovascular and metabolic morbidity in women with previous GDM in a Danish population and to study whether proxies of impaired beta cell function—insulin treatment during GDM pregnancy and development of subsequent manifest diabetes mellitus—influence incident risk of cardiovascular and metabolic morbidity. Methods: A nationwide register-based cohort study was conducted on the complete cohort of 700,648 women delivering in Denmark during 1997–2018. The exposure variable was GDM and primary outcome was overall cardiovascular and metabolic morbidity. Secondary outcomes were major cardiovascular disease (ischemic heart disease, heart failure, and/or stroke/transient cerebral ischemia), hypertension, dyslipidemia, and venous thrombosis. Severity of morbidity was assessed using number of hospital contacts with diagnosis codes related to cardiovascular and metabolic morbidity and number of redemptions of prescribed medication related to cardiovascular and metabolic morbidity in women who developed cardiovascular and metabolic morbidity after pregnancy. Results: The median follow-up period was 10.2–11.9 years with a total range of 0–21.9 years. GDM was associated with increased risk of any cardiovascular and metabolic morbidity (adjusted HR 2.13 [95% CI 2.07–2.20]), major cardiovascular disease (adjusted HR 1.69 [95% CI 1.55–1.84]), hypertension (adjusted HR 1.89 [95% CI 1.82–1.96], dyslipidemia (adjusted HR 4.48 [95% CI 4.28–4.69]), and venous thrombosis (adjusted HR 1.32 [95% CI 1.16–1.50]). Insulin treatment during pregnancy and subsequent development of manifest diabetes exacerbated the risk estimates. Previous GDM was associated with more hospital contacts and more redeemed prescriptions in women developing cardiovascular and metabolic morbidity (p < 0.001). Conclusions: Previous GDM was associated with significantly higher risk of cardiovascular and metabolic morbidity, especially incident dyslipidemia. Risks were exacerbated by proxies of beta cell impairment. Severity of morbidity was significantly worse if GDM preceded cardiovascular and metabolic morbidity.

31 August 2021 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
PDF file
AAAnna J. M. Aabakke
Anna J. M. Aabakke
LKLone Krebs
Lone Krebs
TPTanja G. Petersen
Tanja G. Petersen
FKFrank S. Kjeldsen
Frank S. Kjeldsen
GCGiulia Corn
Giulia Corn
MBMette Bliddal
Mette Bliddal
Introduction: Assessing the risk factors for and consequences of infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) during pregnancy is essential to guide clinical care. Previous studies on SARS‐CoV‐2 infection in pregnancy have been among hospitalized patients, which may have exaggerated risk estimates of severe outcomes because all cases of SARS‐CoV‐2 infection in the pregnant population were not included. The objectives of this study were to identify risk factors for and outcomes after SARS‐CoV‐2 infection in pregnancy independent of severity of infection in a universally tested population, and to identify risk factors for and outcomes after severe infection requiring hospital admission.Material and methods: This was a prospective population‐based cohort study in Denmark using data from the Danish National Patient Register and Danish Microbiology Database and prospectively registered data from medical records. We included all pregnancies between March 1 and October 31, 2020 and compared women with a positive SARS‐CoV‐2 test during pregnancy to non‐infected pregnant women. Cases of SARS‐CoV‐2 infection in pregnancy were both identified prospectively and through register linkage to ensure that all cases were identified and that cases were pregnant during infection. Main outcome measures were pregnancy, delivery, maternal, and neonatal outcomes. Severe infection was defined as hospital admission due to coronavirus disease 2019 (COVID‐19) symptoms.Results: Among 82 682 pregnancies, 418 women had SARS‐CoV‐2 infection during pregnancy, corresponding to an incidence of 5.1 per 1000 pregnancies, 23 (5.5%) of which required hospital admission due to COVID‐19. Risk factors for infection were asthma (odds ratio [OR] 2.19, 95% CI 1.41–3.41) and being foreign born (OR 2.12, 95% CI 1.70–2.64). Risk factors for hospital admission due to COVID‐19 included obesity (OR 2.74, 95% CI 1.00–7.51), smoking (OR 4.69, 95% CI 1.58–13.90), infection after gestational age (GA) 22 weeks (GA 22–27 weeks: OR 3.77, 95% CI 1.16–12.29; GA 28–36 weeks: OR 4.76, 95% CI 1.60–14.12), and having asthma (OR 4.53, 95% CI 1.39–14.79). We found no difference in any obstetrical or neonatal outcomes.Conclusions: Only 1 in 20 women with SARS‐CoV‐2 infection during pregnancy required admission to hospital due to COVID‐19. Risk factors for admission comprised obesity, smoking, asthma, and infection after GA 22 weeks. Severe adverse outcomes of SARS‐CoV‐2 infection in pregnancy were rare.

26 September 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
DGDorte Glintborg
Dorte Glintborg
TPTanja Gram Petersen
Tanja Gram Petersen
KRKatrine Hass Rubin
Katrine Hass Rubin
MAMarianne Skovsager Andersen
Marianne Skovsager Andersen
Aim: To investigate the risk of depression in Danish women with PCOS compared to controls and possible mediators for depression in PCOS. National register-based study in Danish women with PCOS (PCOS Denmark, N = 25,203) and age-matched controls (N = 112,414). PCOS Odense University Hospital (PCOS OUH, N = 998) was a sub-cohort of women with PCOS with available clinical and biochemical results. The main study outcome was depression occurring after PCOS diagnosis. Depression was defined according to hospital ICD-10 diagnosis codes and/or inferred from filled medicine prescription of antidepressants. Diabetes, medical comorbidity, infertility, hormonal anti-contraception and low family income were entered as mediators in Cox regression analyses for depression. In PCOS OUH, PCOS characteristics (age, BMI, Ferriman-Gallwey score) were entered in Cox regression analyses. The median age at cohort entry was 28 (interquartile range (IQR) 23; 35) years. The median follow-up time to incident depression or censuring was 4.8 (IQR 2.2; 8.8) years in PCOS Denmark and 5.2 (IQR 2.4; 9.2) years in controls. Women with PCOS had a 40% increased risk of depression compared to controls (Hazard Ratio 1.42 (95% CI 1.38; 1.47). In regression analyses, diabetes, medical comorbidity, infertility, hormonal anticonception, and low family income were significant mediators of depression. Mediation analyses showed that the proportion of the association explained by diabetes was 12.5% (95% CI 10.4; 14.5). In PCOS OUH, BMI, waist and Ferriman-Gallwey score predicted development of depression. Conclusion: The risk of depression was increased in PCOS. Diabetes was an important mediator of depression in PCOS.

24 February 2025 in Osteoporosis International
Verified
Journal Article
Open access
PDF file
TPTanja Gram Petersen
Tanja Gram Petersen
KRKatrine Hass Rubin
Katrine Hass Rubin
MJMuhammad Kassim Javaid
Muhammad Kassim Javaid
AHAnne Pernille Hermann
Anne Pernille Hermann
KÅKristina E. Åkesson
Kristina E. Åkesson
BABo Abrahamsen
Bo Abrahamsen
Summary Screening initiatives for osteoporosis must facilitate treatment of those at elevated fracture risk. In a randomized controlled trial of 24,229 women, those in the screening group with FRAX ≥ 15% were invited for DXA with AOM treatment offered as per national guidelines. Treatment initiation in the following year was 9.5 times higher compared with controls. Purpose To determine if screened individuals have lower adherence to anti-osteoporotic medication (AOM) than unscreened and to examine determinants for low treatment adherence. Method In 2010/2011, women aged 65–80 (N = 34,229) in the Region of Southern Denmark were invited to the risk-stratified osteoporosis strategy evaluation (ROSE) randomized study. Women in the screening group with moderate to high 10-year fracture risk (FRAX® ≥ 15%) were invited for dual-energy x-ray absorptiometry with AOM treatment as per national guidelines. Screened, controls, and an age-matched general population sample were compared for adherence to AOM using 10-year follow-up data on prescription and hospital records. Results Among ROSE participants with FRAX ≥ 15%, 5864 screened and 5790 controls were eligible for analysis, along with an equal number from the general population. AOM initiation in the first year was 9.5 times higher in screened compared to controls (HR 9.50, 7.16; 12.61). There was no difference in implementation assessed as medication possession ratio. The 5-year persistence rates were similar in screened and controls (51–52%), but lower in the general population (44%). FRAX risk factors partly influenced AOM initiation in the screened, with different patterns in other groups. Immobilization, comorbidities, and co-medications were key determinants of discontinuation in both the short and long term. Conclusion The ROSE screening programme significantly increased treatment initiation in postmenopausal women. Screened women showed similar treatment adherence levels to non-screened once they started medication. However, frail women were more prone to treatment discontinuation, highlighting the need for targeted support in this subgroup. Trial registration The original ROSE trial is registered at ClinicalTrials.gov (NCT01388244). The study protocol has been published in Rubin et al. The risk-stratified osteoporosis strategy evaluation study (ROSE): a randomized prospective population-based study. Design and baseline characteristics. Calcif Tissue Int. 2015;96(2):167–79.

28 May 2026 in European Journal of Pediatrics
Verified
Journal Article
Open access
TPTanja Gram Petersen
Tanja Gram Petersen
GOGunhild Tidemann Okholm
Gunhild Tidemann Okholm
KDKirstine Davidsen
Kirstine Davidsen
RWRikke Wesselhoeft
Rikke Wesselhoeft
MOMerete Osler
Merete Osler
MBMette Bliddal
Mette Bliddal
The purpose of the study is to examine the association between parental mental disorders diagnosed before age six and cognitive ability at age 18, using data from a population-based cohort of male adolescents attending military conscription. Further, we tested whether other childhood adversities modified this association. All males born in Denmark 1996–2001 were linked to national registers. Parental mental disorders were identified from psychiatric hospital diagnoses. We assessed other childhood adversities before age six, including family health-related, socioeconomic, and family instability, as well as the number of adversities experienced. Cognitive scores from the mandatory military conscription were standardized (mean 100, SD = 15). Associations were estimated using multiple linear regression, and effect modification was evaluated using Wald tests. We included 125,791 males (mean age 18 years, SD = 0.66), of whom 6708 had a parent with a mental disorder. Parental mental disorders were associated with a 0.91-point reduced cognitive ability score (95% confidence interval − 1.3, − 0.53). This association was not observed in adolescents who lived with only one parent (− 0.35 (− 0.85, 0.15)), those placed in out-of-home care (3.2 (0.59, 5.8)), and those with ≥ 3 additional adversities before age six. Effect modification tests were statistically significant for these groups ( p < 0.01). Conclusion : Parental mental disorders before age six were associated with a modest reduction in cognitive ability in males at age 18, compared with those without parental mental disorders. Our findings show the association varies across family contexts, although unmeasured genetic and environmental confounding should be considered in interpreting these results. What is Known: • Parental mental disorders are common and linked to lower cognitive ability in offspring .• Childhood adversities often cluster within families and are associated with poorer cognitive outcomes . What is New: • In this nationwide Danish cohort, parental mental disorders before age six were associated with slightly lower cognitive ability at age 18 .• This association was not observed among adolescents with > 2 additional adversities, those who lived with only one parent, or those placed in out-of-home care before age six, suggesting the association varies across family context .

28 September 2026 in Brain and Spine
Verified
Journal Article
Open access
AAAndreas K. Andresen
Andreas K. Andresen
JFJacob Stampe Frølich
Jacob Stampe Frølich
LCLeah Y. Carreon
Leah Y. Carreon
AHAnne Pernille Hermann
Anne Pernille Hermann
TPTanja Gram Petersen
Tanja Gram Petersen
MAMikkel Østerheden Andersen
Mikkel Østerheden Andersen
With the on-going demographic shift towards older populations, osteoporosis is an increasing public health issue. Mortality rates after a hip fracture in the elderly have been extensively studied and reported. However, similar information has not been reported after an osteoporotic vertebral compression fracture (OVCF). What is the mortality rate after a hospital diagnosed OVCF stratified by sex? Using data from the Danish National Health registry, individuals with OVCFs between January 2010 and December 2023 were identified and matched 1:5 with a Control group without OVCF on age, gender, and municipality. Differences in mortality rates at intervals from 30 days to 3 years were calculated and compared for OVCF cases and Controls. A similar analysis was used to explore sex differences for individuals with OVCF. A total of 37,948 patients with OVCF, 12,693 males and 25,255 females were matched with 63,243 and 123,477 Controls, respectively. Individuals with OVCF had statistically significantly higher mortality rates than Controls. Mortality among individuals with OVCF was statistically significantly higher for males than for females. A significantly higher mortality rate among patients with OVCFs compared to non-fracture controls was seen. OVCFs in males were associated with an almost two-fold higher risk of all-cause mortality compared to females. Increased awareness of osteoporosis in the male population and related morbidity should be further addressed in research and clinical practice.